Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Joshua Noone"'
Autor:
Christopher M Blanchette, Anthony P Nunes, Nancy D Lin, Kathleen M Mortimer, Joshua Noone, Krishna Tangirala, Stephen Johnston, Benjamin Gutierrez
Publikováno v:
Drugs in Context, Pp 1-10 (2015)
Background: Risk evaluation and mitigation strategies (REMS), as mandated by the US Food and Drug Administration (FDA) for medications with the potential for harm, are increasingly incorporating rigid protocols for patient evaluation, but little is k
Externí odkaz:
https://doaj.org/article/73c170ca39f74d3bac1caac9f553ca56
Autor:
ALEXANDER BLOOD, LEE-SHING CHANG, CAITLIN A. COLLING, DANIEL GABOVITCH, CAROL M. HAMERSKY, EMILY DURDEN, CASSIE HOLT, JOSHUA NOONE, CHRISTOPHER P. CANNON, DEBORAH J. WEXLER, BENJAMIN M. SCIRICA, FANTA WATERMAN, GRETCHEN STERN, DAVID ZELLE
Publikováno v:
Diabetes. 71
Background: SGLT2i and GLP1-RA improve cardiovascular (CV) and renal outcomes in patients with T2D who are at elevated cardiac or renal risk; however, prescription rates are low despite guidelines recommending their use. We aimed to evaluate the elig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7193dab440f5a5bbc2c8d7e76edc95ef
https://doi.org/10.2337/db22-172-or
https://doi.org/10.2337/db22-172-or
Autor:
MONICA S. FRAZER, CAROLINE SWIFT, MICHAEL LESZKO, ANDREW SARGENT, ERIN BUYSMAN, SARA B. ALVAREZ, JOSHUA NOONE, MICO GUEVARRA
Publikováno v:
Diabetes. 71
Purpose: To describe A1c changes and characteristics of patients with type 2 diabetes mellitus (T2DM) initiating oral semaglutide (sema) , by baseline A1c ≥9% and Methods: Retrospective analysis using medical and pharmacy claims data from 11/01/201
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9429d895466c282263a3dd1d922e64e2
https://doi.org/10.2337/db22-127-lb
https://doi.org/10.2337/db22-127-lb
Autor:
MONICA S. FRAZER, CAROLINE SWIFT, ANDREW SARGENT, MICHAEL LESZKO, ERIN BUYSMAN, SARA B. ALVAREZ, JOSHUA NOONE, CORY L. GAMBLE
Publikováno v:
Diabetes. 71
Purpose: Characterize A1c changes and characteristics among patients with T2DM initiating OW semaglutide (sema) , by baseline A1c ≥9% and Methods: Retrospective analysis using medical and pharmacy claims data between 01/01/2017-12/31/2020 from comm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a84283358a6c9f0c6790b3d19f9e2f10
https://doi.org/10.2337/db22-128-lb
https://doi.org/10.2337/db22-128-lb
Autor:
Hiangkiat Tan, Vincent J. Willey, Michael Radin, Caroline Swift, Simo Du, Nitin Shivappa, Cory Gamble, Joshua Noone
Publikováno v:
Diabetes. 70
Background: With OS’s FDA approval in September 2019, this study sought to provide real-world evidence on its effectiveness in a cohort of early users. Methods: Claims and lab result data were used to identify T2D patients who initiated OS between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::370f19709e1597e0dcde220f536724a8
https://doi.org/10.2337/db21-86-lb
https://doi.org/10.2337/db21-86-lb
Autor:
Joshua Noone, Yurek M. Paprocki, Vincent J. Willey, Simo Du, Caroline Swift, Nitin Shivappa, Hiangkiat Tan
Publikováno v:
Diabetes. 70
Background: This study presents real-world evidence on effectiveness of sema OW in a broad cohort of US commercially insured and Medicare Advantage T2D patients. Methods: Claims and lab result data were used to identify T2D patients who initiated sem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b44330ce65c3af49a9a68e4b816a102
https://doi.org/10.2337/db21-652-p
https://doi.org/10.2337/db21-652-p
Autor:
Caroline Swift, Hiangkiat Tan, Yurek M. Paprocki, Vincent J. Willey, Joshua Noone, Nitin Shivappa, Simo Du
Publikováno v:
Diabetes. 70
Background: This study presents real-world effectiveness of sema OW in a cohort of US commercially insured/Medicare Advantage T2D patients newly initiating a GLP-1 agonist. Methods: Claims and lab result data were used to identify T2D patients who in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::120b80d25809808310776b1a1708c5ce
https://doi.org/10.2337/db21-683-p
https://doi.org/10.2337/db21-683-p
Autor:
Yurek M. Paprocki, Nitin Shivappa, Vincent J. Willey, Joshua Noone, Caroline Swift, Hiangkiat Tan, Simo Du
Publikováno v:
Diabetes. 70
Antidiabetic medication (med) treatment patterns often differ based on a variety of patient and prescriber factors. Understanding these patterns may provide insight on optimizing therapy, especially when considering initiation of a new therapy. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7aafb605c336ce5b3f3befc315a0e839
https://doi.org/10.2337/db21-653-p
https://doi.org/10.2337/db21-653-p
Autor:
Caroline Swift, Joshua Noone, Nitin Shivappa, Simo Du, Yurek M. Paprocki, Vincent J. Willey, Hiangkiat Tan
Publikováno v:
Diabetes. 70
Background: Both primary care physicians (PCPs) and endocrinologists (Endos) commonly prescribe T2D medications. This study presents real-world effectiveness of sema OW by prescriber specialty in a cohort of US commercially insured/Medicare Advantage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba782cd79c72f78de29b654845a5b7c6
https://doi.org/10.2337/db21-1271-pub
https://doi.org/10.2337/db21-1271-pub